Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit

FREE Breaking News Alerts from StreetInsider.com!

More News related to COV

Covidien to Present at Leerink Swann Conference
Nuvo Research announces launch of Synera® in the U.S.
Results from Solitaire with the Intention for Thrombectomy (SWIFT) Study Announced at the International Stroke Conference on February 3
Hercules Technology Growth Capital to Realize Q1 Gain of Approximately $2.2-$2.3 Million from the Sale of Portfolio Company BÂRRX Medical, Inc.

More News related to Corporate News

July 6, 2009 9:07 AM EDT

Covidien (NYSE: COV) announced that Health Canada has approved the Company's Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien's generic product is fully substitutable for Cardiolite(R), a myocardial perfusion imaging agent used for detecting coronary artery disease.

With Health Canada approval of the ANDS, which was filed by the Company's Canadian subsidiary, Covidien's generic product is expected to be available for customers in Canada this summer. The Company's generic product also is available in the U.S., the U.K., Denmark, Germany and Puerto Rico.